Kymera Therapeutics (KYMR) shares were down over 1% in recent Thursday trading after the company reported a Q3 loss, while its collaboration revenue decreased year-over-year and fell short of analyst expectations.
The company reported a Q3 net loss of $0.82 per diluted share, compared with a loss of $0.90 a year earlier.
Analysts polled by Capital IQ expected a $0.84 loss.
Collaboration revenue for the quarter ended Sept. 30 fell to $3.7 million from $4.7 million a year earlier.
Analysts surveyed by Capital IQ expected $10.3 million.
In August, the company raised about $247 million in net proceeds from an equity offering. Kymera said Thursday it extended its cash runway into mid-2027 with the proceeds.
Price: 46.97, Change: -0.70, Percent Change: -1.47
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。